Objectives: The coronavirus outbreak causes a wide range of disease severity. Our study aimed to identify factors affecting the survival of patients with mild to moderate COVID-19 pneumonia by evaluating inflammatory markers, anti-IL6 treatment, clinical parameters, oxygen levels, hospital stay duration, and mortality. Material and Methods: a prospective cohort study that included 96 patients hospitalized for COVID-19 pneumonia. they underwent a thorough history review, vital signs assessment, and measurement of TNFα and IL6 by ELISA and CT chest. Results: The median CT chest severity score was 5. Anti-IL-6 therapy was administered to 22 patients (22.92%). The median hospital stay was 9 days, with a 13.54% mortality rate. Higher oxygen levels at admission were associated with increased survival probability (p<0.001). Conversely, lower TLC, CRP, and IL-6 levels at admission were significantly linked to survival (p=0.04, 0.04, and 0.001, respectively). A smaller CT chest score was also associated with a higher survival probability (p<0.001). the mean survival time of patients receiving anti-IL-6 treatment was 21 days, while patients not receiving the drug was 26 days (p=0.01). Conclusion: Patients treated with anti-IL-6 and received oxygen treatment showed early survival time compared to those who did not. This suggests that disease severity may significantly impact survival outcomes.